Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Go back to Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
(NASDAQ: LTRN) Delayed: 0.68 +0.02 (3.03%)
Previous Close $0.66    52 Week High $ 
Open $0.67    52 Week Low $ 
Day High $0.71    P/E N/A 
Day Low $0.67    EPS $ 
Volume 115,719